syndax.comHome - Syndax
syndax.com Profile
syndax.com is a domain
that was created on 2004-06-29,making it 20 years ago.
It has several subdomains, such as ir.syndax.com , among others.
Discover syndax.com website stats, rating, details and status online.Use our online tools to find owner and admin contact info. Find out where is server located.Read and write reviews or vote to improve it ranking. Check alliedvsaxis duplicates with related css, domain relations, most used words, social networks references. Go to regular site
syndax.com Information
| HomePage size: 43.903 KB |
| Page Load Time: 0.893371 Seconds |
| Website IP Address: 162.159.152.19 |
syndax.com PopUrls
| Syndax: Home https://syndax.com/ |
| Investors | Syndax Pharmaceuticals, Inc. https://ir.syndax.com/ |
| Pipeline https://cms.syndax.com/pipeline/ |
| About Us https://cms.syndax.com/about-us/ |
| Careers https://cms.syndax.com/careers/ |
| Publications & Meeting Presentations https://cms.syndax.com/publications/ |
| News https://cms.syndax.com/news/ |
| Compassionate Use https://cms.syndax.com/compassionate-use/ |
| Privacy Policy https://cms.syndax.com/privacy-policy/ |
| Axatilimab - Syndax https://syndax.com/treatment/axatilimab-sndx-6352/ |
| Press Release Details - Syndax Pharmaceuticals, Inc. https://ir.syndax.com/news-releases/news-release-details/sndx-5613-granted-fda-fast-track-designation-treatment |
| Revumenib - Syndax https://syndax.com/treatment/revumenib-sndx-5613/ |
| Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2022 ... https://ir.syndax.com/news-releases/news-release-details/syndax-pharmaceuticals-reports-fourth-quarter-and-full-year-2022 |
| Pipeline - Syndax https://syndax.com/pipeline/ |
| Entinostat - Syndax https://syndax.com/treatment/entinostat-sndx-275/ |
syndax.com DNS
| A syndax.com. 300 IN A 162.159.153.245 |
| AAAA syndax.com. 300 IN AAAA 2606:4700:7::a29f:99f5 |
| MX syndax.com. 300 IN MX 0 syndax-com.mail.protection.outlook.com. |
| NS syndax.com. 86400 IN NS nick.ns.cloudflare.com. |
| TXT syndax.com. 300 IN TXT 76l7vn9ntnhj9lmee6k7n76o7v |
| SOA syndax.com. 1800 IN SOA nick.ns.cloudflare.com. dns.cloudflare.com. 2341109469 10000 2400 604800 1800 |
syndax.com Httpheader
| Date: Tue, 14 May 2024 22:16:22 GMT |
| Content-Type: text/html; charset=utf-8 |
| Transfer-Encoding: chunked |
| Connection: keep-alive |
| CF-Ray: 883e40948bf624ee-SJC |
| CF-Cache-Status: DYNAMIC |
| Cache-Control: s-maxage=900, stale-while-revalidate |
| ETag: W/"q81pkqzzqvw0u" |
| Vary: Accept-Encoding |
| ki-cache-type: None |
| Ki-CF-Cache-Status: BYPASS |
| ki-edge: v=3.3.2;mv=3.0.6 |
| ki-origin: g1p |
| x-nextjs-cache: HIT |
| x-using: faust |
| Server: cloudflare |
| alt-svc: h3=":443"; ma=86400 |
syndax.com Meta Info
| charset="utf-8"/ |
| content="width=device-width" name="viewport"/ |
| content="index,follow" name="robots"/ |
| content="summary_large_image" name="twitter:card"/ |
| content="Home - Syndax" property="og:title"/ |
| content="https://cms.syndax.com/" property="og:url"/ |
| content="article" property="og:type"/ |
| content="2024-05-09T17:06:36+00:00" property="article:modified_time"/ |
| content="en_US" property="og:locale"/ |
| content="Syndax" property="og:site_name"/ |
| content="17" name="next-head-count"/ |
syndax.com Html To Plain Text
Reimagining Cancer TreatmentMay 9, 2024 Press Release Syndax Announces Participation at the Bank of America Securities 2024 Health Care Conference Read more Who We Are At Syndax, we are advancing the next generation of targeted treatments to realize a future in which people with cancer live longer and better than ever before. We are a clinical stage oncology innovator developing first-in-class therapies for acute leukemias and chronic graft-versus-host disease. Our team is committed to adhering to scientific excellence and dedicated to serving the patient community by delivering therapeutics that provide meaningful and differentiated clinical results and address urgent unmet need. Treatment Pipeline View Pipeline Revumenib Revumenib is a potent, selective, small molecule inhibitor of the menin-KMT2A interaction being developed for the treatment of KMT2A-rearranged acute leukemias, including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and NPM1-mutated AML. Explore More Axatilimab Axatilimab is an investigational monoclonal antibody that targets colony stimulating factor-1 receptor, or CSF-1R, a cell surface protein thought to control the survival and function of monocytes and macrophages, being developed for chronic graft-versus-host disease and idiopathic pulmonary fibrosis. Explore more Featured Content May 9, 2024 Press Release Syndax Announces Participation at the Bank of America Securities 2024 Health Care Conference Read more May 8, 2024 Press Release Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update Read more May 1, 2024 Press Release Syndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024 Read more Explore...
syndax.com Whois
Domain Name: SYNDAX.COM Registry Domain ID: 123713098_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.register.com Registrar URL: http://www.register.com Updated Date: 2023-05-30T08:05:07Z Creation Date: 2004-06-29T16:20:00Z Registry Expiry Date: 2024-06-29T16:20:00Z Registrar: Register.com, Inc. Registrar IANA ID: 9 Registrar Abuse Contact Email: domain.operations@web.com Registrar Abuse Contact Phone: +1.8777228662 Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Name Server: NICK.NS.CLOUDFLARE.COM Name Server: TANI.NS.CLOUDFLARE.COM DNSSEC: unsigned >>> Last update of whois database: 2024-05-17T21:31:56Z <<<